Genetics Of Mortality In Critical Care (GenOMICC) is an open-source research study that aims to engage and unite clinicians and scientists form all over the world to understand the genetic factors that change outcome in critical illness such as (SARS/MERS/Flu) and sepsis. It is the largest study of its kind anywhere in the world. In the UK the GenOMICC study is working with Genomics England and the UK-wide Clusters of Orthologous Groups (COG) viral sequencing group to understand COVID-19.
On 13 May 2020, a major new human whole genome sequencing study was announced to take place across the NHS, involving up to 20,000 people currently or previously in an intensive care unit with coronavirus, as well as 15,000 individuals who have mild or moderate symptoms. Since genetic discoveries need very large numbers of patients, the GenOMICC study ultimately aims to recruit every single COVID-19 patient who is admitted to intensive care in the UK.
Since susceptibility to infection, including sepsis and influenza may be genetically determined, GenOMICC researchers are looking for a genetic link to COVID-19.
The GenOMICC study is supported by Sepsis Research (FEAT), the Intensive Care Society, the Wellcome Trust, and the Medical Research Council. The project is backed by £28 million from Genomics England, UK Research and Innovation, the Department of Health and Social Care and the National Institute for Health Research. Illumina will sequence all 35,000 genomes and share some of the cost via an in-kind contribution.